Researchers have found another piece in the molecular puzzle of changes leading to pulmonary fibrosis — a cell signaling factor. It offers scientists a new target for developing lung-scarring treatments. Lung damage leads to the production of a protein that attracts immune cells to the area. Without this signaling, mice…
Protein That Attracts Immune Cells to Lungs Contributes to Scarring, Study Reports
A factor called Krüpple-like-factor 4, or KLF4, treated lung fibrosis in a mouse model of idiopathic pulmonary fibrosis (IPF) by preventing epithelial cells of the lung from moving into a fibrosis-promoting state, researchers in China report, suggesting its potential as an IPF therapy. The study “Krüpple-like-factor 4 Attenuates Lung…
As I sit down to write this column, I am wiping away tears of frustration. I hope that getting all of my thoughts down on paper will help. I’ll be candid: I am angry at my chronic illness. I don’t have time for it, and neither do the…
Thyroid hormone, delivered through aerosol inhalation, helped to resolve lung scarring in a mouse model of idiopathic pulmonary fibrosis (IPF), according to research published in the journal Nature Medicine. The study provides evidence that lung fibrosis is a disease caused — at least partly — by abnormalities in metabolic processes…
How Pets Benefit Pulmonary Fibrosis Patients
For those of you who are animal lovers, you probably already know that pets can be remarkable companions through illness, injury, loss or throughout any type of recovery period. There are many testimonials and personal stories online about how pets have helped a patient through chronic illness, injury or even…
An anti-inflammatory agent known as ulinastatin decreases pulmonary fibrosis, and at high doses may protect against lung tissue scarring, a study in rats showed. The research, “Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB,” was published in the journal Molecular Medicine Reports.
Understanding Palliative Care
Last week, my husband and I met with a palliative care nurse. A few weeks ago, I shared in another column my frustration with seeking palliative care. Our meeting with this nurse was very helpful. I’ll share what I learned, and I hope it will…
A recent study found that around half of the idiopathic pulmonary fibrosis patients surveyed had not been fully informed about their treatment by their health care team, yet 93 percent of respondents said they wanted to learn about treatments and therapies directly from their doctor rather than other sources. Understanding how…
Everyone diagnosed with a life-threatening disease or chronic illness can have a different experience as a patient. Many factors might cause this, including how involved patients are or want to be in their medical care, the expertise of their physicians, and how rapidly or invasive their disease becomes.
Veracyte has published new data confirming the analytical validity of its Envisia Genomic Classifier to help diagnose idiopathic pulmonary fibrosis (IPF). Its study, “Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia,” appeared in the journal BMC Pulmonary Medicine. The 190-gene Envisia Genomic Classifier helps physicians distinguish between IPF and…
Your PF Community
Recent Posts
- Our response to a PF diagnosis was achieving a ‘life beyond limits’ December 11, 2025
- New IPF treatment moves ahead after encouraging study results December 10, 2025
- A wave of grief can bring sorrow, but also joy December 9, 2025
- FDA grants orphan drug status to experimental IPF treatment FS2 December 3, 2025
- My emergency ‘go bag’ checklist for a transplant hospitalization December 2, 2025
